Remnant Cholesterol Outperforms LDL-C in Predicting Thrombosis Risk in APS Patients: Study Finds

China: New research has highlighted that elevated remnant cholesterol (RC) levels are a significant predictor of recurrent thrombotic events in patients with antiphospholipid syndrome (APS), independent of traditional lipid measures like low-density lipoprotein (LDL) cholesterol.
The study, published in BMC Medicine, found that RC levels above 0.60 mmol/L were associated with a substantially increased risk of all-cause thrombosis (HR 5.05), venous thrombosis (HR 6.34), arterial thrombosis (HR 3.79), and microvascular disease (HR 4.36). The findings suggest that RC could be a more reliable marker for thrombotic risk in APS patients and a potential target for therapeutic intervention.
The researchers note that antiphospholipid syndrome is closely associated with thrombotic events, especially cardiovascular disease (CVD). While the role of remnant cholesterol in predicting CVD risk is well-established, its specific relationship with thrombotic risk in APS patients has not been fully explored. Bin Cai, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China, and colleagues seek to evaluate the association between elevated RC levels and recurrent thrombotic events in individuals with APS, aiming to better understand its potential as a predictive marker in this high-risk population.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.